Case Study Corner: LNP Formulation

04.26.2023

Your biggest challenges inspire us. That's why Emergent supports innovative drug makers that make the seemingly impossible possible. In our latest blog series, Case Study Corner, discover how we've helped our clients overcome their biggest challenges during the development and manufacturing process.

Summary: A mid size biotech company partnered with Emergent to characterize a multi-step lipid nanoparticle formulation process for a Phase III mRNA-LNP vaccine.

20211111-EBSI_Gaithersburg-0047-of-0052_9538NIKON Z 7-RS

Emergent CDMO

Case Studies Development Services Nanoparticles

04.27.2020

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19

GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)

Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby...

06.29.2023

Case Study Corner: Streamlining R&D to Manufacturing

Your biggest challenges inspire us. That's why Emergent supports innovative drug makers that make the seemingly impossible...

06.01.2020

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...